Sentences with phrase «work in cancer cell»

Timothy Wang at Columbia recently published work in Cancer Cell (DOI: 10.1016 / j.ccell.2016.11.005) that showed that recruitment of nerves into the tumor microenvironment is necessary and sufficient for stomach cancer progression, and that blocking a neurotransmitter in the nerves that line the stomach could represent a novel therapy.

The Herlyn Laboratory seeks to further define the various signaling pathways that work in cancer cells in order to discover new opportunities to inhibit cancer growth through targeted therapeutics.

A drug that prevents myosin from working in cancer cells could keep them from invading other cells or metastasize into different organs.

Not exact matches

Chemotherapy works by killing cancer cells by targeting fast - dividing cells, and in most cases, kills off some healthy cells along the way, including nerve cells in the brain.

BioNTech, which has around 700 employees at sites in Germany — more than any other unlisted biotech firm in Europe — is also working on other cancer - fighting technologies, including antibodies, cell therapies and small molecules.

The lab that I work in is primarily interested in understanding how and why certain cancers are more likely to spread to the skeleton, and my personal project has focused on uncovering new mechanisms that the cancer cells use to communicate with other cells in the bone.

In one respect the first look is unnerving, because the chemical mechanisms that seem to drive the cancer cell astray are not different in kind from mechanisms at work in the normal celIn one respect the first look is unnerving, because the chemical mechanisms that seem to drive the cancer cell astray are not different in kind from mechanisms at work in the normal celin kind from mechanisms at work in the normal celin the normal cell.

Recent collaborative work between UCR and Cedars - Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone.

The compound (right panel) has a scorpion - like shape with two arms grabbing EphA2 - expressing cancer cells, and a tail (brown) constituted by a cytotoxic chemotherapeutic agent (paclitaxel used in this work).

«The fine particles of this drug allow for it to be released slowly and stay in the abdomen,» said Katherine Roby, Ph.D., research associate professor in the Department of Anatomy and Cell Biology at KU Medical Cancer, who started her pre-clinical work on Nanotax more than a decade ago.

Previous work in Weinberg's lab had shown that after a tumor forms in one part of the body, some of the cancer cells undergo EMT, Mani explains.

For some years now, a new class of drugs called antibody - drug conjugates (ADCs) have been used, which work in two ways: they consist of an antibody that binds selectively to the tumor cell receptor and interrupts the signal to propagate; they also act as a transport vehicle for a chemical substance that enters the cancer cells with the antibody and triggers their death.

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells» resistance to paclitaxel.

Skin Cancer cells work together to spread further and faster, according to a new study published in Cell Reports.

«Our work strongly supports that cancer stem cells are the main source of growth in these tumors and, as such, should be considered promising targets for treatment,» says Mario Suvà, MD, PhD, of the MGH Department of Pathology, co-senior author of the Nature paper.

While researchers have long worked with nanoparticles for drug delivery, the findings put forth by He and his team represent a crucial breakthrough in addressing multidrug resistance in cancer cells.

In addition to using healthy cells to do their work for them, cancer cells also slowly destroy the skin's immune defence mechanism.

For some cancer patients, viruses engineered to zero in on tumor cells work like a wonder drug.

Recent work shows the biggest ones are abundant in many cancer cells but not healthy cells and that these circles may aid the cancer's evolution and recurrence.

Previous work in the lab of CU Cancer Center investigator, Carol Sartorius, PhD, and others shows that progesterone aids the expansion of CK5 + cells.

She was on her way out to a pub after a scientific conference when she spotted Paul Nurse, who was working on cell - cycle regulation at Imperial Cancer Research Fund in London.

However, along with this seemingly linear storyline in which retinoids block progesterone's promotion of CK5 + cells, previous work in the lab of CU Cancer Center investigator Peter Kabos, MD, and others shows that breast cancers treated with anti-estrogen drugs like tamoxifen or aromatase inhibitors show an increased population of CK5 + cells — it is as if these therapies remove the roadblock of estrogen - dependent cells, leaving CK5 + cells to proliferate.

Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body's immune system detect and attack cancerous cells.

«Different types of cancer cells with different strengths and weaknesses are both present in the tumor at the same time and can work together to spread faster and more efficiently.

In a continuation of this work, Goldman is also using mathematical modeling to pursue the most effective dose of chemotherapy to induce the vulnerable transition state of the cancer cell demonstrated in this researcIn a continuation of this work, Goldman is also using mathematical modeling to pursue the most effective dose of chemotherapy to induce the vulnerable transition state of the cancer cell demonstrated in this researcin this research.

«Our work suggests a mechanism for cell lethality involving the regulation of BCAAs as crucial elements in pancreatic cancer by regulating ME3,» said Ronald DePinho, M.D., professor of Cancer Biology, senior author of the Nature paper and president of MD Andcancer by regulating ME3,» said Ronald DePinho, M.D., professor of Cancer Biology, senior author of the Nature paper and president of MD AndCancer Biology, senior author of the Nature paper and president of MD Anderson.

Although Coley couldn't explain precisely why or how his toxins worked, modern immunotherapy treatments help T - cells in the immune system to recognize specific cancer cells and attack them.

He needed a stem cell transplant, which is a normal treatment for leukemia, but his cancer needed to be in remission first, and the chemotherapy wasn't working.

The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret's lab, builds on a first - of - its - kind human - cell model of pancreatic cancer progression the lab described in 2013.

«As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that.»

The findings were published recently in the Journal of the National Cancer Institute by a group that includes Rony A. François, an M.D. / Ph.D. student working with Maria Zajac - Kaye, Ph.D., an associate professor in the UF College of Medicine's department of anatomy and cell biology.

But their overriding interest in BPTES, says Slusher, was in how it works: by blocking the production of glutamine, an amino acid that acts as a building block of cells and is used frequently by pancreatic cancers to create more cancer cells.

Maria Zajac - Kaye, Ph.D., an associate professor in the College of Medicine's department of anatomy and cell biology, and Rony François, an M.D. / Ph.D. student who works with her, found a new drug combination that inhibits one form of pancreatic cancer tumor and kills its cells.

Using the same computer - based approach, the team has now been able to target the c - FLIP (cellular FLICE [FADD - like IL - 1β - converting enzyme]- inhibitory) protein, known to play a key role in cancer stem cell maintenance and survival, described in previously published work by the Institute.

CAR - T cell therapy is particularly exciting because it works well in people whose cancers haven't responded to other available treatments, says Renier Brentjens, an oncologist at Memorial Sloan Kettering Cancer Center in New York City.

This work is being done in collaboration with Dr. Hasan Korkaya, assistant professor, Biochemistry and Molecular Biology at the Medical College of Georgia, who has developed drug - resistant cell lines, and with breast cancer clinicians.

UT Southwestern Medical Center cancer researchers have identified a protein critical to the spread of deadly cancer cells and determined how it works, paving the way for potential use in diagnosis and eventually possible therapeutic drugs to halt or slow the spread of cancer.

Cells suspended in a stiff matrix were more likely to work their way through the matrix to other side of a serum gradient, analogous to how metastasizing cancer cells break free from their tuCells suspended in a stiff matrix were more likely to work their way through the matrix to other side of a serum gradient, analogous to how metastasizing cancer cells break free from their tucells break free from their tumors.

«The challenge is finding targets that exist on other types of cancer cells but not on normal cells,» says pediatric oncologist Stephan Grupp of the Children's Hospital of Philadelphia, who worked with Porter on testing the treatment in mice.

«Despite the low infection levels of mouse cells with oHSV, we were able to cause a delay in tumor growth in one of the cancer models and even cure many of the mice in a second model,» said first author Jennifer Leddon, who conducted much of the laboratory work during a research experience in the Center for Childhood Cancer and Blood Discancer models and even cure many of the mice in a second model,» said first author Jennifer Leddon, who conducted much of the laboratory work during a research experience in the Center for Childhood Cancer and Blood DisCancer and Blood Diseases.

Tom Misteli, a cell biologist at the National Cancer Institute in Bethesda, Maryland, considers the map a «framework for future work.»

Epigenetic therapies are thought to work in two ways to fix these errors in cancer cells — by correcting the «position» of the gene switches and by making the cell appear as though it's infected by a virus, triggering the immune system.

In one, researchers working with mice at the Institute of Molecular and Cellular Biology in Singapore used antibodies to target proteins inside cancer cells — an impressive feat, since the antibodies were long considered too large to cross the cancer cell's outer membranIn one, researchers working with mice at the Institute of Molecular and Cellular Biology in Singapore used antibodies to target proteins inside cancer cells — an impressive feat, since the antibodies were long considered too large to cross the cancer cell's outer membranin Singapore used antibodies to target proteins inside cancer cells — an impressive feat, since the antibodies were long considered too large to cross the cancer cell's outer membrane.

The work published in Cancer Cell complements previous research efforts from the CNIO Melanoma Group, which could lead to the development of novel drugs that selectively target the mechanism of cell autodigestion as a potential therapeutic stratCell complements previous research efforts from the CNIO Melanoma Group, which could lead to the development of novel drugs that selectively target the mechanism of cell autodigestion as a potential therapeutic stratcell autodigestion as a potential therapeutic strategy.

Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable «nanoparticles» able to carry DNA to brain cancer cells in mice.

«We haven't held out much hope for immune therapy to work in them because before you can enter cancer cells to knock them down, you have to be able to get inside.

«Hodgkin lymphoma is unusual among cancers in that it consists of a small number of tumor cells in a sea of inflammatory cells and immune system cells, including T cells that don't work very effectively.»

Working with human breast cancer cells and mouse models of breast cancer, scientists identified a new protein that plays a key role in reprogramming cancer cells to migrate and invade other organs.

Working with human breast cancer cells and mice, scientists at The Johns Hopkins University say new experiments explain how certain cancer stem cells thrive in low oxygen conditions.

Batimastat does not work this way: instead, it is designed to keep cancers in check by preventing malignant cells breaking away and forming secondary tumours elsewhere in the body.